Received Nov 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Administration of flulaval after a temperature excursion; Administration boostrix after a temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in an unspecified number of patients who received Flu Seasonal TIV Quebec (FluLaval 2025-2026 season) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received FluLaval 2025-2026 season and Boostrix. On an unknown date, an unknown time after receiving FluLaval 2025-2026 season and not applicable after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: Administration of flulaval after a temperature excursion) and incorrect storage of drug (Verbatim: Administration boostrix after a temperature excursion). The outcome of the incorrect storage of drug and incorrect storage of drug were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-NOV-2025 The reporter reported a temperature for FluLaval and Boostrix. According to reporter, during all October the vaccines had been exposed to low temperatures, the lowest being 29.3-degree F. According to reporter, the exposure was of 14 hours every day, and she did not know the exact number of days the vaccines were exposed to low temperatures. Reporter mentioned that an unknown number of doses of these two vaccines were administered to an unknown number of patients after the temperature excursions. The reporter consented to follow up. The batch number was not provided upon follow up with the reporter.